Skip to main content
SpringerLink
Log in

Assessment of Medication and Recreational Drugs Associated with Fatigue

  • Chapter
  • First Online:
Fatigue Management

  • 939 Accesses

Abstract

Fatigue is a prevalent condition that increases the risk of errors, contributes to accidents, and impairs quality of life. Causes of fatigue include various medications and recreational agents. With the ever-increasing list of medications approved for managing chronic medical conditions, it can be difficult to ascertain the role of the agents in provoking or exacerbating fatigue. This is especially true when the medical condition for which the agent is prescribed is itself associated with fatigue. A detailed history is a crucial process for establishing the causal relationship between a psychoactive substance and fatigue. The temporal relationship between initiation and/or administration of a medicine and the onset of fatigue represents the most important clue. Sometimes, removal of the presumed agent and close follow-up of a patient is needed to ascertain such a role. With that in mind, there are certain groups of agents that may cause fatigue. In this chapter, we review pharmacological and recreational agents associated with fatigue.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    Merriam-Webster Online

References

  1. Helfand M, Peterson K, Christensen V, Dana T, Thakurta S. Drug class review: beta adrenergic blockers: final report update. Drug Class Reviews. 2009.

    Google Scholar 

  2. Butler J, Khadim G, Belue R, Chomsky D, Dittus RS, Griffin M, Wilson JR. Tolerability to beta-blocker therapy among heart failure patients in clinical practice. J Card Fail. 2003;9:203–9.

    Article  CAS  PubMed  Google Scholar 

  3. Ko DT, Hebert PR, Coffey CS, Curtis JP, Foody JM, Sedrakyan A, Krumholz HM. Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med. 2004;164:1389–94.

    Article  CAS  PubMed  Google Scholar 

  4. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351–7.

    Article  CAS  PubMed  Google Scholar 

  5. Pechan J, Mikulecky M, Srbecky M. Acute haemodynamic effect of metoprolol in essential hypertension. Cor Vasa. 1988;30:51–9.

    PubMed  CAS  Google Scholar 

  6. Pechan J, Ondrejicka M, Janotka M, Kellerova E. The effect of guanethidine and propranolol on capillary blood flow in subcutaneous tissue and muscle in essential hypertension. Cardiology. 1974;59:172–83.

    Article  CAS  PubMed  Google Scholar 

  7. Velasco A, Solow EB, Price AL, Wang Z, Arbique D, Arbique G, Adams-Huet B, Schwedhelm E, Lindner JR, Vongpatanasin W. Differential effects of nebivolol vs metoprolol on microvascular function in hypertensive humans. Am J Physiol Heart Circ Physiol. 2016;311:H118.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906.

    Article  CAS  PubMed  Google Scholar 

  9. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–31.

    Article  CAS  PubMed  Google Scholar 

  10. Guay DR. Trandolapril: a newer angiotensin-converting enzyme inhibitor. Clin Ther. 2003;25:713–75.

    Article  CAS  PubMed  Google Scholar 

  11. Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens. 2011;13:639–43.

    Article  CAS  Google Scholar 

  12. Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014:CD010509.

    Google Scholar 

  13. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–223.

    Article  Google Scholar 

  14. Citrome L, Eramo A, Francois C, Duffy R, Legacy SN, Offord SJ, Krasa HB, Johnston SS, Guiraud-Diawara A, Kamat SA, et al. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatr Dis Treat. 2015;11:3095–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Miller BJ. A review of second-generation antipsychotic discontinuation in first-episode psychosis. J Psychiatr Pract. 2008;14:289–300.

    Article  PubMed  Google Scholar 

  16. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1050–60.

    Article  PubMed  Google Scholar 

  17. Phan SV. Medication adherence in patients with schizophrenia. Int J Psychiatry Med. 2016;51:211–9.

    Article  PubMed  Google Scholar 

  18. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1–46.

    PubMed  Google Scholar 

  19. Kemp DE. Managing the side effects associated with commonly used treatments for bipolar depression. J Affect Disord. 2014;169(Suppl 1):S34–44.

    Article  CAS  PubMed  Google Scholar 

  20. Brix FN, Hein SS, Staehelin JT. Management of painful neuropathies. Handb Clin Neurol. 2013;115:279–90.

    Article  Google Scholar 

  21. Doerr JP, Spiegelhalder K, Petzold F, Feige B, Hirscher V, Kaufmann R, Riemann D, Voderholzer U. Impact of escitalopram on nocturnal sleep, day-time sleepiness and performance compared to amitriptyline: a randomized, double-blind, placebo-controlled study in healthy male subjects. Pharmacopsychiatry. 2010;43:166–73.

    Article  CAS  PubMed  Google Scholar 

  22. U.S. Department of Health and Human Services. Alzheimer’s. 3 Oct 2016. Ref type: online source.

    Google Scholar 

  23. Mevaag M, Henning O, Baftiu A, Granas AG, Johannessen SI, Nakken KO, Johannessen LC. Discrepancies between physicians’ prescriptions and patients’ use of antiepileptic drugs. Acta Neurol Scand. 2016;135:80.

    Article  CAS  PubMed  Google Scholar 

  24. Kowski AB, Weissinger F, Gaus V, Fidzinski P, Losch F, Holtkamp M. Specific adverse effects of antiepileptic drugs—a true-to-life monotherapy study. Epilepsy Behav. 2016;54:150–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This work is supported by the Department of Veterans Affairs Research and Development Care Line.

Author information

Authors and Affiliations

  1. Department of Medicine, Baylor College of Medicine, Houston, TX, USA

    Amir Sharafkhaneh MD, PhD

  2. Medical Care Line, Michael E. DeBakey VA Medical Center, Houston, TX, USA

    Amir Sharafkhaneh MD, PhD

  3. Division of Public Mental Health and Population Sciences, School of Medicine, Stanford University, Stanford, CA, USA

    Max Hirshkowitz PhD

  4. Department of Medicine, Baylor College of Medicine, Houston, TX, USA

    Max Hirshkowitz PhD

  5. Department of Medicine, Pulmonary, Critical Care and Sleep Section, Baylor College of Medicine and The Michael E. DeBakey Veterans Administration Hospital, Houston, TX, USA

    Mary Rose PsyD

Authors
  1. Amir Sharafkhaneh MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary Rose PsyD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Max Hirshkowitz PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amir Sharafkhaneh MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Medicine, Baylor College of Medicine, Houston, Texas, USA

    Amir Sharafkhaneh

  2. Division of Public Mental Health and Population Sciences, School of Medicine, Stanford University, Stanford, California, USA

    Max Hirshkowitz

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media, LLC, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sharafkhaneh, A., Rose, M., Hirshkowitz, M. (2018). Assessment of Medication and Recreational Drugs Associated with Fatigue. In: Sharafkhaneh, A., Hirshkowitz, M. (eds) Fatigue Management. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-8607-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-8607-1_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-8605-7

  • Online ISBN: 978-1-4939-8607-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation